New antibody combo aims to stop High-Risk myeloma in its tracks
NCT ID NCT07029776
First seen Nov 06, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests whether two bispecific antibodies (teclistamab and talquetamab) given in sequence can improve survival in 50 people with high-risk multiple myeloma. Participants will receive chemotherapy, immunotherapy, and possibly a stem cell transplant depending on how well the cancer responds. The goal is to achieve a complete response and keep the cancer from returning for at least two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72120, United States
Conditions
Explore the condition pages connected to this study.